article thumbnail

Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret

Fierce Pharma

Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22

article thumbnail

Novartis headquarters raided in Swiss competition authority's patent probe

Fierce Pharma

Novartis headquarters raided in Swiss competition authority's patent probe. Thu, 09/15/2022 - 10:15.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck fined $38M in Spain for hindering generic competition for NuvaRing

Fierce Pharma

Merck fined $38M in Spain for hindering generic competition for NuvaRing. Tue, 10/25/2022 - 11:18.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

Competition in Healthcare is Increasing—Rapidly and Dramatically

Healthcare Success

What’s more, your highest revenue service lines are likely already facing stiff competition from all angles. . For these reasons and more, it’s imperative to identify your unique selling propositions, review them, and revise them regularly to remain competitive. . So, how can your brand stay competitive? The answer is twofold.

article thumbnail

Is the launch environment really more competitive now?

pharmaphorum

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. Continued competitive intensity. The first in class launches barely have time to establish before they face competition, and then the competition keeps on coming.

article thumbnail

FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition

MedCity News

The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests. The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion.